Abstract 1751P
Background
Myxoid liposarcoma (MLPS) constitutes around 15% of all liposarcoma. They are characterized by a specific translocation, the t(12;16), leading to the fusion of FUS to DDIT3, which confers specific molecular features. In this study, we assessed the clinical and survival data of MLPS pts (patients) with evaluation of the impact of various clinical and tumor features on survival outcomes.
Methods
This retrospective study included MLPS pts treated at Gustave Roussy between January 1990 and March 2024. All clinical features were gathered as well as survival data and management details. In addition, we performed univariate (UVA) and multivariate analyses (MVA) to evaluate the impact of various factors on survival (age, gender, adjuvant chemotherapy (CT) and radiation therapy (RT), primary site, and tumor grade (TG)).
Results
336 pts were included (median age of 43 yrs and 60.4% were men). They occurred in the lower arms (75.3%, 253 pts, most in the hip (73.1%)), followed by the trunk (9.8%, 33 pts). TG 1 tumor was in 172 pts (64.7%), TG 2 in 85 (31.9%), and TG 3 in 9 (3.4%). 311 pts had surgery (93.9%) of whom 165 had adjuvant RT (53.1%) while 78 received peri-operative CT (25.1%). Out of 317 pts, 85 had at least one local relapse (LR) (26.8%) with a median time to LR of 24.3 mo. At 6 mo, the LR-free survival (LR-FS) was 96% while the 1- and 5-year LRFS reached 92.2% and 75.8%. 95 had at least one metastatic relapse (MR) (30.3%) with a median time of 38.3 mo. [25.9;45.7]. At 6 mo., the MRFS was 98% while the 1- and 5-year reached 94.8% and 70.6%. The median OS was not reached (NR) [249; NR]. At 6 mo., the OS was 98.8% while the 1- and 5-year were 97.7% and 89.3%. In the UVA, adjuvant RT (p<0.001) and CT (p=0.008) had an impact on LR while in the MVA, adjuvant RT (p<0.001) and age (p=0.03) were significant. Male gender (p=0.01) and high TG (p=0.02) had a higher risk of MR as well as shorter survival (male gender (p=0.04) and TG (p=0.004)).
Conclusions
In one of the largest retrospective cohorts, 336 MLPS pts were commonly diagnosed with a tumor in the lower arms with a localized setting. It is characterized by a high risk of both local (26.8%) and distant relapse (30.3%) but with prolonged survival. Male gender and a higher tumor grade were associated with an increased risk of distant relapse and shorter survival.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1352P - Real-world second-line outcomes of NSCLC patients receiving first-line chemotherapy plus immunotherapy
Presenter: Marco Russano
Session: Poster session 06
1353P - Efficacy and safety of docetaxel in combination with nintedanib or ramucirumab following immune checkpoint-Inhibitor treatment in patients with non-small cell lung cancer
Presenter: Konstantinos Ferentinos
Session: Poster session 06
1354P - Retrospective audit to determine the effect of antibiotic therapy on immune checkpoint inhibitor efficacy in stage IV NSCLC
Presenter: Deevyashali Parekh
Session: Poster session 06
1356P - Transcriptomic inflammatory profiling of non-small cell lung cancer: Insights from a 7-gene expression analysis
Presenter: Elba Marin
Session: Poster session 06
1357P - Multicenter phase II study of cisplatin and gemcitabine plus necitumumab in patients with unresectable, advanced lung squamous cell carcinoma who have progressed on or after initial treatment with immune checkpoint inhibitors plus platinum-based chemotherapy: WJOG14120L NESSIE study
Presenter: Hiroshige Yoshioka
Session: Poster session 06
1358P - Plinabulin/docetaxel versus docetaxel in survival benefits of 2L/3L EGFR wild-type NSCLC after platinum regimens (DUBLIN-3): A randomized phase III trial
Presenter: Trevor Feinstein
Session: Poster session 06
1359P - Lack of Abscopal effect and radiotherapy-induced lymphocyte depletion in advanced non-small cell lung cancer (NSCLC) patients treated with atezolizumab and radiotherapy
Presenter: Alexander Meisel
Session: Poster session 06
1361P - The Stereotactic Radiosurgery-Brain Prognostic Index (SRS-BPI): A novel prognostic index for lung cancer patients with brain metastases eligible for SRS
Presenter: Andreas Koulouris
Session: Poster session 06